Liver Cirrhosis

The supplied grounding supports several common aetiologic categories for cirrhosis, including viral hepatitis, alcohol-related liver disease, and non-alcoholic fatty liver disease. The literature also links metabolic dysfunction and steatosis-related liver injury to progression toward fibrosis and cirrhosis.

Chronic liver inflammation drives fibrogenesis, with inflammatory cells activating hepatic stellate cells, which are a major source of myofibroblasts in the liver. The gut-liver axis is also implicated, with bidirectional signaling between the intestine, its microbiota, and the liver contributing to liver injury and homeostasis. Cytokine-mediated inflammatory signaling and altered microbial communities are part of the described disease biology.

Risk is increased by the major underlying causes of cirrhosis, especially chronic viral hepatitis, alcohol exposure, and non-alcoholic fatty liver disease. Metabolic dysfunction, obesity, type 2 diabetes mellitus, and hepatic steatosis are also supported as associated risk contexts in the grounding.

The grounding supports management at the level of etiologic therapy, non-etiologic therapy, drug therapy, diet therapy, and complication management. For portal hypertension and compensated cirrhosis, the literature emphasizes risk stratification and personalized care, including prevention of first decompensation and management of acute bleeding. Semaglutide is mentioned as a co-studied drug, but the supplied material does not support a specific cirrhosis treatment recommendation for it.